Pfizer plans to build sterile injectables site
Pfizer has announced plans to build “one of the most technically advanced sterile injectable pharmaceutical production facilities in the world”, strengthening the US firm’s capability to produce and supply “critical, life-saving injectable medicines” for patients globally.
You may also be interested in...
Pfizer is ending operations at two Indian manufacturing sites, including one with a checkered regulatory history. Approximately 1,700 jobs are at stake as a result of the action, though the US multinational clarified that it is not making a widespread exit from Indian manufacturing.
This month, long-awaited new pricing measures in Canada will come into force, while several trials will either kick off or end, including a liability opioids case involving Teva in San Francisco and Hatch-Waxman litigation over Otsuka/Lundbeck’s Rexulti.
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.